Recursion, a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world’s largest source of make-on-demand small molecules.

Recursion，一家领先的临床阶段技术生物公司，致力于解码生物学以彻底改善生活，今天宣布生成了利用其人工智能/机器学习平台（Recursion OS）工具的筛选库，并结合了全球最大的按需合成小分子来源——Enamine的REAL Space。

Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized compounds designed to accelerate drug discovery against 100 key and clinically relevant drug targets in difficult to address biological areas..

这两家公司共同精选了10个经过优化的筛选库，这些库包含了超过15,000种新合成的化合物，旨在加速针对100个关键且具有临床相关性的药物靶点的药物发现，特别是在那些难以解决的生物学领域。

Enamine’s REAL Space represents the continuously expanding chemical library built on insights from millions of parallel syntheses. While the chemical space offers incredible potential, the sheer volume of compounds, numbering in the tens of billions, makes it difficult to select the most promising candidates.

Enamine的REAL Space代表了基于数百万并行合成实验见解而不断扩展的化学库。尽管这一化学空间提供了巨大的潜力，但化合物的数量高达数千亿，要从中筛选出最有前景的候选者变得十分困难。

By combining the expansive REAL Space with the Recursion OS to predict small molecule compatibility with protein targets, the collaboration allows for the creation of smaller, highly focused libraries that outperform traditional high-throughput screening (HTS) collections..

通过将广阔的REAL空间与递归操作系统相结合，以预测小分子与蛋白质靶标的兼容性，这种合作能够创建规模更小、高度聚焦的化合物库，其性能优于传统的高通量筛选（HTS）集合。

'We have been using the Recursion OS to identify compounds across Enamine’s vast chemical space for our own internal discovery needs,' said Chris Gibson Co-Founder and CEO of Recursion. 'This collaboration allows us to extend that approach to areas of biology that are of general interest to the industry.

“我们一直在使用Recursion操作系统来识别Enamine庞大化学空间中的化合物，以满足我们内部的发现需求，” Recursion的联合创始人兼首席执行官Chris Gibson表示。“此次合作使我们能够将这种方法扩展到行业内普遍感兴趣的生物学领域。”

We are bringing together the best of both worlds—Enamine’s vast chemical library and Recursion’s AI-driven drug discovery platform to help expand the drug discovery toolset.'.

我们正在将两个世界的优势结合在一起——Enamine庞大的化学库和Recursion的AI驱动药物发现平台，以帮助扩展药物发现工具集。

These curated compound libraries are an output of a research collaboration between Recursion and Enamine, whereby Recursion gained access to tens of thousands of compounds that it individually predicted may interact with the functional areas of biology not addressed by its current 1.2M compound library in exchange for helping to develop libraries of broad commercial interest..

这些精心策划的化合物库是Recursion与Enamine之间研究合作的成果，根据合作，Recursion获得了成千上万种化合物的访问权，它单独预测这些化合物可能会与其当前120万化合物库未涵盖的生物学功能领域产生相互作用，作为交换，Recursion帮助开发了具有广泛商业兴趣的化合物库。

“Enamine’s REAL has enormous discovery opportunities. While it has previously been utilized in ultra-large virtual screening campaigns, it has never been explored at scale across multiple targets. Our partnership with Recursion allows us to tap into their cutting-edge technology to rapidly uncover novel compounds with high potential in various research fields rapidly.

“Enamine的REAL具有巨大的发现机会。虽然它之前已被用于超大规模虚拟筛选活动，但从未在多个目标上进行过规模化探索。我们与Recursion的合作使我们能够利用其前沿技术，快速发掘在各个研究领域具有高潜力的新型化合物。”

We are ready to launch this new generation of compound libraries to support our customers’ hit-finding campaigns, secured by rapid access to analogues from REAL,” added Andrey Tolmachov, CEO and Founder of Enamine..

“我们已经准备好推出新一代化合物库，以支持客户的筛选活动，并通过REAL快速获取类似物来确保安全。” Enamine的首席执行官兼创始人安德烈·托尔马切夫补充道。

For more information about the curated compound libraries, visit Enamine’s website here: https://enamine.net/compound-libraries

有关精选化合物库的更多信息，请访问 Enamine 的网站：https://enamine.net/compound-libraries

About Recursion

关于递归

Recursion is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias.

Recursion是一家处于临床阶段的科技生物公司，通过解码生物学来彻底改善生活，引领行业发展。支撑其使命的是Recursion操作系统，这一平台整合了多种技术，持续生成世界上规模最大的专属生物和化学数据集之一。Recursion利用先进的机器学习算法，从数据集中提炼出数万亿条跨生物学和化学的可搜索关系，且不受人类偏见的限制。

By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine..

通过指挥大规模的实验规模 —— 每周多达数百万次湿实验室实验 —— 以及巨大的计算规模 —— 拥有并运营世界上最强劲的超级计算机之一，Recursion 正在将技术、生物学和化学结合起来，推动医学的未来。

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn..

Recursion总部位于盐湖城，是犹他州生命科学产业联盟BioHive的创始成员之一。Recursion还在多伦多、蒙特利尔、纽约、伦敦、牛津地区以及旧金山湾区设有办事处。欲了解更多信息，请访问www.Recursion.com，或在X（原Twitter）和LinkedIn上关注我们。

About Enamine

关于Enamine

Enamine is a scientifically driven integrated discovery Contract Research Organisation with unique partnering opportunities in exploring new chemical space. The company combines access to the in-house produced screening compounds (4.5M in stock) and building blocks (350K in stock) with a comprehensive platform of integrated discovery services to advance and accelerate the efforts in Drug Discovery.

Enamine是一家以科学为驱动的综合发现合同研究组织，拥有探索新化学空间的独特合作机会。该公司将自主生产的筛选化合物（库存450万）和构建模块（库存35万）与全面的综合发现服务平台相结合，以推动和加速药物发现的工作进程。

For more information visit: https://enamine.net.

更多信息请访问：https://enamine.net。

About Enamine REAL® Space

关于Enamine REAL®空间

Enamine REAL® Space contains 64.9 billion make-on-demand molecules that can be synthesized at Enamine extremely fast (3-4 weeks), with high feasibility (over 80%), and inexpensive. The REAL compounds are created by parallel chemistry through the compilation of 143,000 building blocks via more than 167 well-validated parallel synthesis protocols, underlying Enamine’s approach to design make-on-demand compounds to maximize synthesis success rate.

Enamine REAL® Space 包含 649 亿个按需合成的分子，这些分子可以在 Enamine 极速合成（3-4 周），具有高可行性（超过 80%），且成本低廉。REAL 化合物通过并行化学方法创建，利用超过 167 种经过充分验证的并行合成协议，将 143,000 个构建块进行编译，这是 Enamine 设计按需化合物以最大化合成成功率的方法基础。

For more information visit: https://enamine.net/compound-collections/real-compounds.

有关更多信息，请访问：https://enamine.net/compound-collections/real-compounds。

For more information about the new collaboration or to learn more about the curated compound libraries, please contact:

如需了解更多关于新合作的信息或了解更多关于精选化合物库的信息，请联系：

Contact Information

联系方式

Yurii Moroz, PhD

尤里·莫罗兹，博士

VP of Sales and Marketing, Enamine

Enamine公司销售与市场副总裁

y.moroz@enamine.net

y.moroz@enamine.net

https://enamine.net

https://enamine.net

Forward-Looking Statements

前瞻性声明

This document contains information that includes or is based upon 'forward-looking statements' within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the collaboration with Enamine and the ability to enhance the precision, speed, and efficiency of drug discovery efforts; Recursion’s leadership of the TechBio space; the Recursion OS and other technologies; and all other statements that are not historical facts.

本文件包含根据1995年《证券诉讼改革法》所定义的“前瞻性陈述”之信息，包括但不限于以下内容：与Enamine的合作及其在提升药物发现工作的精确性、速度和效率方面的能力；Recursion在TechBio领域的领导地位；Recursion OS及其他技术；以及所有非历史事实的其他陈述。

Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described und.

前瞻性声明可能包含也可能不包含诸如“计划”、“将”、“预期”、“预计”、“打算”、“相信”、“潜力”、“继续”等识别性词语以及类似术语。这些声明受到已知或未知的风险和不确定性的影响，可能导致实际结果与这些声明中明示或暗示的结果存在重大差异，包括但不限于：药物研发所固有的挑战，包括临床前和临床试验的时间安排及结果，由于疗效不足、安全性问题或其他因素，在任何阶段（无论是在获得监管批准之前还是之后）都存在高失败风险；我们利用并提升药物发现平台的能力；我们为开发活动及其他公司目的获取融资的能力；我们合作活动的成功与否；我们获得监管批准并最终实现候选药物商业化的能力；我们获取、维持和执行知识产权保护的能力；针对我们的技术系统进行的网络攻击或其他中断；我们吸引、激励和留住关键员工并管理增长的能力；通货膨胀及其他宏观经济问题；以及如其他部分所述的其他风险和不确定性。

Media Contact

媒体联系人

Media@Recursion.com

媒体@递归.com

Investor Contact

投资者联系

Investor@Recursion.com

投资者@Recursion.com

Source: recursion.com

来源：recursion.com